Patrick Machado's Net Worth
$40.7 Million
Who is Patrick Machado?
Patrick Machado has an estimated net worth of $40.7 Million. This is based on reported shares across multiple companies, which include Turning Point Therapeutics, Inc., ACELYRIN, Inc., Xenon Pharmaceuticals Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., CHIMERIX INC, INOTEK PHARMACEUTICALS CORP, Arcus Biosciences, Inc., Adverum Biotechnologies, Inc., Urovant Sciences Ltd., Principia Biopharma Inc., Axovant Sciences Ltd., SCYNEXIS INC, MEDIVATION, INC., ENDOCYTE INC, Turnstone Biologics Corp., and ALUMIS INC..
SEC CIK
Patrick Machado's CIK is 0001311210
Past Insider Trading and Trends
2012 was Patrick Machado's most active year for acquiring shares with 13 total transactions. Patrick Machado's most active month to acquire stocks was the month of May. 2012 was Patrick Machado's most active year for disposing of shares, totalling 28 transactions. Patrick Machado's most active month to dispose stocks was the month of January. 2014 saw Patrick Machado paying a total of $2,117,000.00 for 234,042 shares, this is the most they've acquired in one year. In 2014 Patrick Machado cashed out on 401,580 shares for a total of $15,730,630.40, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Turning Point Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ACELYRIN, Inc. (SLRN) Snapshot price: $4.25
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 7
| |||
Form 4
|
∞
| 14.68K |
—
|
—
| 14.68K |
Oct 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Xenon Pharmaceuticals Inc. (XENE) Snapshot price: $38.47
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Arbutus Biopharma Corp (ABUS) Snapshot price: $4.5488
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Myovant Sciences Ltd. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +6.32% | 2.42M |
$8.25 | $19,999,996.50 | 40.77M |
Jun 4
| |||
Form 4
| +2.98% | 1.11M |
$20.27 | $22,500,004.05 | 38.34M |
Apr 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||